Search results
Results from the WOW.Com Content Network
Two generic oral tablets of glimepiride, 2 mg each. Glimepiride is indicated to treat type 2 diabetes; its mode of action is to increase insulin secretion by the pancreas. However it requires adequate insulin synthesis as prerequisite to treat appropriately. It is not used for type 1 diabetes because in type 1 diabetes the pancreas is not able ...
A 2011 Cochrane review showed a HbA1c reduction of 0.20% more with Exenatide 2 mg compared to insulin glargine, exenatide 10 μg twice daily, sitagliptin and pioglitazone. [27] Exenatide, together with liraglutide, led to greater weight loss than glucagon-like peptide analogues.
[1] [2] It is not indicated for use by itself in type 1 diabetes. [1] [2] It is taken by mouth. [1] [2] Effects generally begin within half an hour and can last for up to a day. [1] Common side effects include nausea, diarrhea, low blood sugar, and headache. [1] Other side effects include sleepiness, skin rash, and shakiness. [3]
If a patient using an alpha-glucosidase inhibitor suffers from an episode of hypoglycemia, the patient should eat something containing monosaccharides, such as glucose tablets. Since the drug will prevent the digestion of polysaccharides (or non-monosaccharides), non-monosaccharide foods may not effectively reverse a hypoglycemic episode in a ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
in the morning max. maximum maximum mcg microgram: recommended replacement for "μg" which may be confused with "mg" mdi metered dose inhaler m.d.u. more dicto utendus: to be used as directed mEq milliequivalent mg milligram mg/dL milligrams per deciliter MgSO4 magnesium sulfate: may be confused with "MSO4", spell out "magnesium sulfate" midi
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.